> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Releases Revised Triumeq, Dovato Labels
- URL: https://www.fdaweb.com/fda-releases-revised-triumeq-dovato-labels/
- Published: 2021-03-11T12:00:00.000Z
- Updated: 2026-09-14T16:50:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148862

FDA has released labeling revisions approved for ViiV’s Triumeq (abacavir/dolutegravir/lamivudine) to include dosing in patients with creatine clearance between 30 and 49 mL per min. An online [post](https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/food-and-drug-administration-approved-revisions-triumeq-abacavirdolutegravirlamivudine-and-dovato?ref=fdaweb.com) says additional drug interaction information for Triumeq and riociguat was included in the label. Similar changes were made to the label for ViiV’s Dovato (dolutegravir/lamivudine).

The post shows changes made to the Dosage and Administration, Use in Specific Populations, Drug Interactions, and Clinical Pharmacology sections of the labels.